- Home
- RLX vs NAMS Comparison
RLX vs NAMS Comparison
Compare RLX & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLX
- NAMS
- Stock Information
- Founded
- RLX 2018
- NAMS 2019
- Country
- RLX China
- NAMS Netherlands
- Employees
- RLX N/A
- NAMS N/A
- Industry
- RLX Medicinal Chemicals and Botanical Products
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- RLX Health Care
- NAMS Health Care
- Exchange
- RLX Nasdaq
- NAMS Nasdaq
- Market Cap
- RLX 3.3B
- NAMS 2.7B
- IPO Year
- RLX 2021
- NAMS N/A
- Fundamental
- Price
- RLX $2.28
- NAMS $23.55
- Analyst Decision
- RLX Strong Buy
- NAMS Strong Buy
- Analyst Count
- RLX 1
- NAMS 7
- Target Price
- RLX $2.76
- NAMS $38.17
- AVG Volume (30 Days)
- RLX 5.4M
- NAMS 581.4K
- Earning Date
- RLX 03-14-2025
- NAMS 02-06-2025
- Dividend Yield
- RLX 0.44%
- NAMS N/A
- EPS Growth
- RLX 607.62
- NAMS N/A
- EPS
- RLX 0.07
- NAMS N/A
- Revenue
- RLX $307,798,132.00
- NAMS $33,594,000.00
- Revenue This Year
- RLX $116.31
- NAMS $131.53
- Revenue Next Year
- RLX $46.01
- NAMS N/A
- P/E Ratio
- RLX $32.18
- NAMS N/A
- Revenue Growth
- RLX 99.79
- NAMS 78.77
- 52 Week Low
- RLX $1.50
- NAMS $15.19
- 52 Week High
- RLX $2.37
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- RLX 72.82
- NAMS 44.17
- Support Level
- RLX $2.13
- NAMS $22.53
- Resistance Level
- RLX $2.23
- NAMS $26.71
- Average True Range (ATR)
- RLX 0.09
- NAMS 0.97
- MACD
- RLX -0.00
- NAMS -0.45
- Stochastic Oscillator
- RLX 70.77
- NAMS 23.89
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.